Longevity Medical Institute launches intranasal brain therapy platform

Longevity Medical Institute has launched a regenerative neurology program in San José del Cabo that uses an intranasal delivery system to move selected therapies toward the brain without a lumbar puncture. The institute says the platform expands treatment options alongside intrathecal care for patients with neurological disorders.

Why it matters: - Longevity Medical Institute is adding a non-invasive route for selected neurological treatments. - The new platform could give physicians another option when intrathecal administration is not the best fit. - The launch targets a long-standing challenge in neurology: getting therapies past the blood-brain barrier.

What happened: - Longevity Medical Institute announced the launch of its Regenerative Neurological Therapy Program on July 23, 2026, in San José del Cabo, Baja California Sur, Mexico. - The program features an advanced intranasal delivery platform designed to transport regenerative therapies through the nasal cavity toward the brain. - The institute says the platform is intended as a non-invasive alternative to intrathecal administration for selected neurological conditions.

The details: - Intrathecal administration remains a direct way to deliver therapies into cerebrospinal fluid, but it requires a lumbar puncture. - The intranasal system targets the upper nasal cavity near the olfactory region instead of the lower nasal passages. - Research has shown that compounds delivered to the olfactory region may travel toward the brain through the olfactory and trigeminal nerve pathways. - The delivery system uses an electronically controlled nebulizer instead of a traditional spray pump. - The nebulizer creates microscopic aerosol droplets and delivers them gradually over several minutes. - The design is meant to increase contact time in the olfactory region, reduce medication loss into the throat, and improve delivery consistency. - Longevity Medical Institute uses the platform exclusively for regenerative therapies, including mesenchymal stem cells, MSC-derived exosomes, and selected therapeutic peptides. - Treatment recommendations are individualized by the institute's multidisciplinary physician team after neurological evaluation. - The evaluation may include advanced imaging, laboratory testing, neurological examination, and review of medical history. - The institute says its broader neurological program also includes intravenous regenerative therapies, intrathecal administration in a fully licensed operating room when indicated, hyperbaric oxygen therapy, advanced neurological imaging, and multidisciplinary physician care. - For more information about the program, the institute directs readers to the company's announcement.

Between the lines: - The launch reflects growing interest in delivery methods that may improve access to the central nervous system without increasing procedural burden. - The institute is positioning the platform as a precision option, with delivery method chosen based on diagnosis, clinical findings, and treatment goals. - Human clinical research on MSCs and MSC-derived exosomes has reported encouraging safety findings across several neurological conditions, but the release also notes that larger randomized trials are still needed. - The emphasis on physician-guided planning suggests the institute is trying to frame the program as evidence-based rather than experimental marketing.

What's next: - Longevity Medical Institute says larger randomized clinical trials are still needed to clarify which patients are most likely to benefit and how durable treatment responses may be. - The institute expects regenerative neurological therapies to remain a fast-growing area of translational medicine. - Patients seeking program details can visit more information.

The bottom line: - Longevity Medical Institute is betting that intranasal, nose-to-brain delivery can broaden access to regenerative neurology while avoiding some of the invasiveness of intrathecal treatment.